| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.960565 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20260521134034 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 260304e202604 onc ob f000 0 eng d |
|---|
| 020 | |a9780660987644 |q(statement) |
|---|
| 020 | |a9780660987651 |q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-401/2026E-PDF |
|---|
| 086 | 1 |aHP40-401/2026-1E-PDF |
|---|
| 245 | 00|aUpdated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease. |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cApril 2026. |
|---|
| 264 | 4|c©2026 |
|---|
| 300 | |a1 online resource (51 pages) + |esummary (4 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Recommandations mises à jour sur les vaccins contre le virus respiratoire syncytial (VRS) chez les adultes âgés et les adultes à risque élevé de maladie grave liée au VRS. |
|---|
| 500 | |a"An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI)"--Cover. |
|---|
| 500 | |a"Pub.: 250483." |
|---|
| 500 | |a"Pub.: 250485." |
|---|
| 500 | |aReplaced with updated version at the publisher's request (May 21, 2026). |
|---|
| 504 | |aIncludes bibliographical references (pages 36-42). |
|---|
| 650 | 0|aRespiratory syncytial virus|xVaccination|xGovernment policy|zCanada. |
|---|
| 650 | 0|aViral vaccines|xGovernment policy|zCanada. |
|---|
| 650 | 0|aImmunization of older people|xGovernment policy|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tRecommandations mises à jour sur les vaccins contre le virus respiratoire syncytial (VRS) chez les adultes âgés et les adultes à risque élevé de maladie grave liée au VRS.|w(CaOODSP)9.960570 |
|---|
| 856 | 40|qPDF|s0.99 MB|uhttps://publications.gc.ca/collections/collection_2026/aspc-phac/HP40-401-2026-eng.pdf|z(statement) |
|---|
| 856 | 40|qPDF|s303 KB|uhttps://publications.gc.ca/collections/collection_2026/aspc-phac/HP40-401-2026-1-eng.pdf|z(summary) |
|---|